Related Experiment Video
Updated: Jul 2, 2026
09:39
Creation of Reversible Cholestatic Rat Model
Published on: May 21, 2011
15.1K
Reversine attenuates cholestatic ductular reaction in rats
Di Huang1,2, Lijuan Tang3, Tianyang Li1
1Department of Surgery, Guangzhou First People's Hospital, Guangzhou, China.
FEBS Open Bio
|March 17, 2023
Summary
Reversine effectively reduced ductular reaction and liver fibrosis in cholestatic rats by inhibiting biliary epithelial cell proliferation and Notch signaling. This suggests reversine
Area of Science:
- Hepatology and Gastroenterology
- Cell Biology
- Pharmacology
Background:
- Ductular reaction (DR) is a common feature in biliary and liver disorders, including nonalcoholic fatty liver disease.
- Limited research exists on interrupting DR in cholestatic conditions.
- Bile duct ligation (BDL) in rats is a model for inducing cholestatic liver injury and DR.
Purpose of the Study:
- To investigate the impact of reversine on ductular reaction (DR) in a rat model of cholestatic liver injury.
- To analyze the effects of reversine on biliary epithelial cell (BEC) proliferation, gene expression, and fibrosis.
- To explore the underlying molecular mechanisms, including Notch signaling, affected by reversine.
Main Methods:
- Cholestatic liver injury was induced in rats via bile duct ligation (BDL).
- Reversine was administered intraperitoneally to rats for two weeks to assess its in vivo effects on DR and fibrosis.
- Biliary epithelial cells (BECs) were isolated for in vitro analysis of proliferation and gene expression following chemically induced formation, with reversine treatment.
Main Results:
- BDL rats exhibited significant DR, characterized by increased biliary epithelial cell (BEC) expansion and expression of markers like CK7, CK19, and EpCAM.
- BDL-induced DR cells showed elevated expression of proliferation genes (Ki67, Foxm1, Pcna) and biliary markers (Krt7, Krt19, Epcam, Sox9, Cftr, Asbt).
- Reversine treatment attenuated cholestatic fibrosis and DR in vivo, decreasing BEC formation and downregulating Krt7, Cftr, and Ggt1 gene expression in vitro. BDL-induced Notch activation was also attenuated by reversine, partly via the Notch/Sox9 pathway.
Conclusions:
- Reversine effectively mitigates ductular reaction and liver fibrosis in a rat model of cholestasis.
- The drug reduces bile duct formation by influencing the Dlk1/Notch/Sox9 signaling pathway.
- Reversine shows potential as a therapeutic agent for cholangiopathies by preventing ductular reactions.
